Biogen Claims Lead Among Adalimumab Biosimilars In Europe

With quarterly sales up to $36m, Biogen says its Imraldi rival to Humira is the market-leading adalimumab biosimilar in Europe.

Winner
Biogen claims it is the leading biosimilar adalimumab player in Europe • Source: Shutterstock

Biogen believes that its Imraldi adalimumab biosimilar is outperforming other rivals to AbbVie’s Humira reference biologic in Europe. “Our data indicate that Imraldi is the market-leading Humira biosimilar in Europe,” chief financial officer Jeff Capello told investors.

Having developed the biosimilar through its Samsung Bioepis joint venture with Samsung Biologics, Biogen launched Imraldi in Europe on 17...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.